This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Ariad Pharmaceutical's Iclusig May Relieve Shareholders' Pain: StockTwits

Stocks in this article: ARIA

NEW YORK (TheStreet) -- Ariad Pharmaceuticals  (ARIA) released positive data Sunday for a drug intended to treat types of gastrointestinal tumors. The company said that initial data in its Phase 2 trial of Iclusig showed it has "anti-tumor activity" in patients with advanced gastrointestinal tumors that have proven resistant to other treatments.

Ariad rose nearly 10% in premarket trading to $7.09. By 10:30 a.m. the stock settled back to the $6.80 range, still up nearly 6%.

The overwhelming majority of traders on called for the stock to go higher. Sentiment on the stock is 96% bullish, according to StockTwits analytics.

@SyntecVentures @FoxW Ill keep buying. These people know I'm not a seller of this stock till 20. It will be there by end of year ? Jared Mastroianni (@Stockbroker) Jun. 2 at 05:03 AM

The Phase 2 trial is ongoing. There are 35 patients involved and the FDA lifted a partial hold preventing Ariad from enrolling new patients.

$ARIA Solid science, solid leadership, minor setback. Time to recover & exceed!! This is Ariad goal, not sell cheap to please retail shares ? Sully (@SullyinFL) Jun. 2 at 07:27 AM

The FDA enacted the hold in October after some patients treated with Ariad's drug developed blood clots in their arteries. The prescriber's warning label for Iclusig says at least 27% of patients treated with the drug suffered a clot in arteries or veins. Patients with and without cardiovascular risk factors, including patients less than 50 years old, had clots. Heart failure, including fatalities, occurred in 8% of Iclusig-treated patients. The stock had dropped 59% on the October news.

$ARIA Morning all. Glad to see some love finally. Rough few months but patience pays. Cheers to a good day! ? Ben Parker (@Bparker5512) Jun. 2 at 07:51 AM

While side effects including a clot-induced stroke or heart attack are frightening, Iclusig is intended for people whose cancer type leaves them few other options. Patients can only enroll in the study if they have gastrointestinal stromal tumors that have spread to other organs and/or cannot be removed via surgery. In addition, they must also have cancer mutations that have made other treatments ineffective, such as tyrosine-kinase inhibitor treatments, which target cancers by interrupting signals to create more proteins that cause the tumor to spread.

Every year, 5,000 more people are diagnosed with gastrointestinal stromal tumors, according to the U.S. National Library of Medicine. The five-year survival rate for people who have such tumors and have had them spread to nearby organs is nearly 75%, according to

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs